Device to evaluate blood clotting under real flow conditions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to develop a device that assesses primary hemostasis, which is the body's initial response to stop bleeding, under conditions that mimic actual blood flow. Current tests focus on individual components like platelets or von Willebrand factor, but do not account for the complexities of whole blood and flow dynamics. By using a device that simulates a blood vessel, the study seeks to better identify bleeding risks in patients with von Willebrand disease, major constitutional thrombopathy, or those on antiplatelet therapy. Participants will provide blood samples as part of routine testing to evaluate the device's performance.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* person who has given oral consent
* adult
* blood donor at EFS Bourgogne Franche-Comté
* or patient with von Willebrand disease or major constitutional thrombopathy followed by the Resource and Competence Centre (CRC) - Constitutional Hemorrhagic Diseases of Dijon or Besançon
* or patient on antiplatelet drugs consulting for thrombosis at the Dijon Bourgogne or Besançon Hospital

Exclusion Criteria:

* a person who is not affiliated to or not a beneficiary of national health insurance
* person subject to court-ordered protection (curatorship, guardianship)
* pregnant, parturient or breastfeeding woman
* a person who is unable to consent
* person on anti-inflammatory treatment and serotonin reuptake inhibitor antidepressants (platelet function disorders)

Where it's running

• CHU de Besançon
  Besançon, France Recruiting
• CHU Dijon Bourgogne
  Dijon, France Recruiting

Study contacts

• Study coordinator: Emmanuel De Maistre
• Email: emmanuel.demaistre@chu-dijon.fr
• Phone: 03 81 61 56 15

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ATHNdataset registry for people with bleeding and clotting disorders

  This registry collects health, treatment, and patient-reported information from people with bleeding and clotting disorders seen at ATHN-affiliated centers to help improve care and outcomes.

  Recruiting American Thrombosis and Hemostasis Network · Hickory, North Carolina · NCT06820515

• Prophylactic treatment for heavy menstrual bleeding in women with von Willebrand disease

  This study tests if a new treatment can help women with von Willebrand disease who have heavy menstrual bleeding feel better during their periods.

  Recruiting at 2 sites Phase 3 Unity Health Toronto · Kingston, Ontario and 1 other locations · NCT06205095

• Progestin options for heavy periods in young people with inherited bleeding disorders

  This project will test two progestin menstrual treatments—a levonorgestrel IUD and daily norethindrone acetate—in adolescents and young adults (ages 10–24) with inherited bleeding disorders to see which better reduces heavy menstrual bleeding over six months.

  Recruiting at 6 sites Oregon Health and Science University · Palo Alto, California and 7 other locations · NCT05916469

• Evaluating VGA039 in Healthy Volunteers and Patients with Von Willebrand Disease

  This study is testing a new treatment called VGA039 to see if it is safe and effective for healthy people and those with von Willebrand Disease.

  Recruiting at 24 sites Phase 1/2 Vega Therapeutics, Inc · Los Angeles, California and 24 other locations · NCT05776069

• Understanding cardiovascular and thromboembolic events in patients with von Willebrand disease in the French West

  This study looks at how often blood clots and heart rhythm problems happen in adults with von Willebrand disease in the French West to better understand their risks.

  Recruiting University Hospital, Brest · Angers and 5 other locations · NCT05773638

• Long-term observation of non-cancer blood disorders

  This study is tracking people with blood disorders like hemophilia and thrombosis for at least 15 years to see how their conditions change over time and gather useful information for doctors and researchers.

  Recruiting at 74 sites American Thrombosis and Hemostasis Network · Phoenix, Arizona and 75 other locations · NCT04398628

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.